In addition, Eisai must conduct a post-authorization safety study, including setting up a patient registry for the European Union. Now each European country must set its own rules for access and ...

The blood-brain barrier border protects the brain by regulating the flow of molecules, peptides, and cells, but it also keeps ...

Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing ...

For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical practice. Now, they are on the cusp. At this year’s ADPD conference, held ...

In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease pathology with remarkable accuracy (see Part 7 of this series). How ...

Cerebrospinal fluid and plasma markers are now being used to help diagnose Alzheimer’s in memory clinics, but what about using them to stage the disease? That’s the next big step, said Henrik ...

Member reports the following financial or other potential conflicts of interest: E. Solje has served on the advisory board of Novartis, EISAI, Lilly and Roche, served as a consult for Novo Nordisk, ...

Jean-François Démonet trained as an MD and Neurologist (1987) at Toulouse University; training in Neuropsychology at Montreal University and in brain imaging in R. Frackowiak’s lab in London UK with a ...